Cite

    Bridget E Barber et al.. “Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.” Lancet infectious diseases, vol. 22, no. 6, 2022, pp. 879–890. http://access.bl.uk/ark:/81055/vdc_100155168052.0x000019